Veeva Sys Inc Stock Price, News & Analysis

BioMarin (NASDAQ: BMRN) and Veeva Systems (NYSE: VEEV) announced a long-term enterprise agreement on January 8, 2026 to expand their existing relationship.

The partnership aims to increase speed, agility and operational efficiency in developing and commercializing therapies by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products, and to optimize the healthcare professional and patient experience. Company leaders highlighted the collaboration's role in accelerating access to transformative medicines globally.

Veeva (NYSE: VEEV) announced Veeva Environmental Monitoring, a cloud-native application within Veeva Quality Cloud designed to automate environmental sample scheduling, collection, and analysis for manufacturing QC. The solution is unified with Veeva LIMS and integrates with Veeva quality applications to reduce data silos and paper-based processes, automatically initiate quality events in Veeva QMS, surface procedures from Veeva QualityDocs, and publish environmental data to Veeva Batch Release to help optimize batch release.

The company said Veeva Environmental Monitoring is planned for availability in December 2026 and is positioned to modernize QC, micro labs, and batch-release workflows.

Veeva Systems (NYSE: VEEV) announced that Novo Nordisk's International Operations has committed to adopt Veeva Vault CRM to support commercial teams with next‑generation CRM capabilities and agentic AI.

Vault CRM is described as part of a suite of applications and agentic AI designed for commercial execution across personal and digital channels and to address global, country‑specific business and compliance requirements. Both companies framed the move as an expansion of their strategic partnership and a technology foundation to help drive commercial execution.

Veeva (NYSE: VEEV) announced on Jan. 5, 2026 that its board approved a share repurchase program authorizing up to $2.0 billion of Class A common stock purchases.

The program may use open-market purchases, privately negotiated transactions, or Rule 10b5-1 trading plans and will comply with Rule 10b-18 and other applicable laws. The program term is 2 years, repurchases are at management discretion, and Veeva is not obligated to buy any specific number of shares; the program may be suspended or cancelled at any time.

Veeva (NYSE: VEEV) will present at the Raymond James 2025 TMT and Consumer Conference in New York on Monday, December 8, 2025 at 11:20 a.m. ET. Presenters will be Brian Van Wagener, CFO, and Paul Shawah, EVP Strategy. The presentation will be available via live webcast, with an archived replay posted afterward on Veeva's investor relations site.

Investors can access the live and archived webcast at https://ir.veeva.com.

Veeva Systems (NYSE: VEEV) announced on December 3, 2025 that Veeva AI Agents are now available for Vault CRM and PromoMats, delivering industry-specific AI inside Veeva applications.

Initial agents include Free Text Agent, Voice Agent, and Pre-call Agent for Vault CRM, plus Quick Check Agent and Content Agent for PromoMats. Agents operate with direct, secure access to data within existing permissions and audit trails, and customers can configure or build custom agents. Additional agents for clinical, regulatory, safety, quality, medical, and commercial are planned throughout 2026. Veeva Business Consulting will support process design and change management as customers adopt agents.

Veeva Systems (NYSE: VEEV) announced that Roche Pharmaceuticals will extend its partnership by adopting Veeva Vault CRM across Roche's global pharma organization, expanding Veeva's commercial footprint.

The announcement highlights that Veeva AI — described as agentic, industry-specific AI — will power Vault CRM with four planned AI agents: Free Text Agent, Voice Agent, Pre-call Agent, and Media Agent, which are planned for availability in December 2025.

The release frames the move as enabling more personalized HCP interactions and improved insights for field teams, without disclosing financial terms or contract value.

Veeva (NYSE: VEEV) reported fiscal 2026 third quarter results for the period ended October 31, 2025: Total revenues $811.2M (up 16% YoY) and Subscription services $682.5M (up 17% YoY). Operating income was $240.9M (+33% YoY) and non-GAAP operating income was $364.9M (+20% YoY). Net income was $236.2M (+27% YoY) and non-GAAP net income was $345.1M (+20% YoY).

Veeva highlighted progress on Veeva AI, Vault CRM customer additions, and Development Cloud wins. Guidance: Q4 revenue $807–$810M; FY revenue $3,166–$3,169M; non-GAAP FY diluted EPS ~$7.93.

Veeva Systems (NYSE: VEEV) announced on November 4, 2025 that more than 100 biotechs across 60 companies have adopted Veeva Basics to standardize clinical, regulatory, and quality operations. Veeva Basics uses pre-configured, pre-validated applications on the Vault Platform for fast deployment and seamless upgrade to full Vault solutions.

Two new applications—Veeva LIMS Basics and Veeva PromoMats Basics—are planned for availability in early 2026, with stability functionality for LIMS planned for 2026. More information at veevabasics.com.